论文部分内容阅读
目的:探讨卵巢浆液性癌患者血清nidogen-2和糖类抗原125(carbohydrate antigen125,CA125)的检测及其临床意义。方法:应用ELISA法和化学发光法分别检测15例卵巢正常者、22例卵巢浆液性囊腺瘤患者和40例卵巢浆液性囊腺癌患者血清nidogen-2和CA125水平。结果:卵巢浆液性囊腺癌患者血清nidogen-2水平明显高于卵巢正常者和卵巢浆液性囊腺瘤患者(P<0.05),卵巢正常者和卵巢浆液性囊腺瘤患者血清nidogen-2水平无明显差异;Ⅲ～Ⅳ期卵巢浆液性囊腺癌患者的血清nidogen-2水平明显高于Ⅰ～Ⅱ期患者(P<0.05)。Nidogen-2和CA125联合检测可提高卵巢浆液性囊腺癌诊断的灵敏度和特异度。结论:Nidogen-2有望成为一种新的卵巢浆液性癌的标志物。
Objective: To investigate the serum levels of nidogen-2 and carbohydrate antigen 125 (CA125) in patients with ovarian serous carcinoma and its clinical significance. Methods: The serum levels of nidogen-2 and CA125 in 15 patients with normal ovarian tissue, 22 patients with ovarian serous cystadenoma and 40 patients with ovarian serous cystadenocarcinoma were detected by ELISA and chemiluminescence. Results: The serum nidogen-2 level in patients with ovarian serous cystadenocarcinoma was significantly higher than that in normal ovarian and ovarian serous cystadenomas (P <0.05). The serum nidogen-2 level in patients with normal ovarian serous cystadenoma and ovarian serous cystadenoma No significant difference; Ⅲ ~ Ⅳ ovarian serous cystadenocarcinoma serum nidogen-2 levels were significantly higher than Ⅰ ~ Ⅱ patients (P <0.05). Combined detection of Nidogen-2 and CA125 can improve the sensitivity and specificity of ovarian serous cystadenocarcinoma diagnosis. Conclusion: Nidogen-2 is expected to become a new marker of ovarian serous carcinoma.